results and those from Roth and coworkers. They evaluated insomniac individuals only (none with dementia) and observed significant impairment of short-term memory and verbal learning by assessments done in days 1 and 7 after onset of drug administration. It should be considered that short-term studies may not result in full development of the therapeutic effects of a drug with the inconvenience of revealing first-hand, usually transient adverse effects. Also, cognitive and psychomotor benefits experienced by healthy and demented volunteers can vary in magnitude and relevance in perspective of the nature and intensity of the impairment, ranging from substantial gains in performance (sustained or not) to a flatter slope of decline. In our scenario of a minimum follow-up of 3 weeks (including 2 weeks under intervention), witnessing no worsened performance at all among trazodone-treated compared to placebo-treated counterparts may contribute to assume trazodone as a safe drug in the context of cognitively compromised patient. To witness no change in cognitive functions regardless of the benefits of trazodone use in sleep parameters suggests that gains in the primary target do not necessarily translate into improvement of secondary goals, at least not in the settings described. Moreover, instructions regarding attainment to important sleep hygiene principles were discussed by the medical physician with all volunteers’ caregivers upon start of the interventional stage of the study. But our data reveal no change in the cognitive measures as result of these recommendations (placebo group), prompting for the discussion of whether behavioral strategies alone are to be considered before pharmacological intervention.

To our knowledge, no study has examined the effect of trazodone on cognition in patients with AD. Among the limitations of our study, one may include that participation was restricted to AD patients with SD, being therefore difficult to extrapolate our findings to other dementia. Also, despite the rigorous execution of the study, assessing all possible cognitive dimensions was beyond the scope of our design, and make room for subsequent analyses. At last, the rather small and nonprobabilistic sample size could be viewed as a limitation. In conclusion, this study provides evidence that usage of trazodone 50 mg does not impact cognition after a 2-week treatment period of AD patients. More studies are needed to measure effects of trazodone on other cognitive dimension in older adults.

**REFERENCES**

1. Vermeeren A, Coenen AM. Effects of the use of hypnotics on cognition. *Prog Brain Res*. 2011;190:89–103.
2. Gunja N. In the Zzz zone: the effects of Z-drugs on human performance and driving. *J Med Toxicol*. 2013;9:163–171.
3. James SP, Mendelson WB. The use of trazodone as a hypnotic: a critical review. *J Clin Psychiatry*. 2004;65:752–755.
4. Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. *J Clin Psychiatry*. 2005;66:469–476.
5. Bossini L, Casolari I, Koukoua D, et al. Off-label uses of trazodone: a review. *Expert Opin Pharmacother*. 2012;13:1707–1717.
6. Stahl SM. *Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications*. 3rd ed. Cambridge: NY: Cambridge University Press; 2008.
7. Roth AJ, McCall WV, Liguori A. Cognitive, psychomotor and polysomnographic effects of trazodone in primary insomniacs. *J Sleep Res*. 2011;20:552–558.
8. Rush CR, Madakasira S, Hayes CA, et al. Trazodone and triazolam: acute subject-rated and performance-impairing effects in healthy volunteers. *Psychopharmacology*. 1997;131:9–18.
9. Camargos EF, Louzada LL, Quintas JL, et al. Trazodone improves sleep parameters in Alzheimer disease patients: a randomized, double-blind, and placebo-controlled study. *Am J Geriatr Psychiatry*. 2014;22:1565–1574.
10. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res*. 1975;12:189–198.
11. Wechsler D. *WAIS-III Wechsler Memory Scale*. 3rd ed. San Antonio, TX: Psychological Corporation; 1997, manual.
12. Wechsler D. *WAIS-III Wechsler Adult Intelligence Scale*. 3rd ed. San Antonio, TX: Psychological Corporation; 1997, manual.
13. Greenblatt DJ, Friedman H, Burstein ES, et al. Trazodone kinetics: effect of age, gender, and obesity. *Clin Pharmacol Ther*. 1987;42:193–200.
14. Burns M, Moskowitz H, Jaffe J. A comparison of the effects of trazodone and amitriptyline on skills performance by geriatric subjects. *J Clin Psychiatry*. 1986;47:252–254.
15. Sasada K, Iwamoto K, Kawano N, et al. Effects of repeated dosing with mirtazapine, trazodone, or placebo on driving performance and cognitive function in healthy volunteers. *Hum Psychopharmacol*. 2013;28:281–286.
16. Obermann KR, Morris JC, Roe CM. Exploration of 100 commonly used drugs and supplements on cognition in older adults. *Alzheimers Dement*. 2013;9:724–732.
17. Riedel WJ, Mehta MA, Unema PJ. Human cognition assessment in drug research. *Curr Pharm Des*. 2006;12:2525–2539.

**AUTHOR DISCLOSURE INFORMATION**

The authors declare no conflicts of interest.

**IEEE Francisco Camargos, MD, PhD**
Geriatric Medical Centre
Brasilia University Hospital and Graduation Program in Medical Sciences
University of Brasilia
Brasilia, Brazil
einstein@unb.br

**Juliana Lima Quintas, MsC (Psych)**
Luciana Lilian Louzada, MD, MsC
Geriatric Medical Centre
Brasilia University Hospital
University of Brasilia
Brasilia, Brazil

**Janeth O.S. Naves, PhD (Pharm)**
Geriatric Medical Centre
Brasilia University Hospital and Graduation Program in Health Sciences
Pharmacy School
University of Brasilia
Brasilia, Brazil

**Audrey C.T. Furioso, MsC (Biol)**
Otávio Toledo Nobrega, PhD (Biol)
Geriatric Medical Centre
Brasilia University Hospital and Graduation Program in Medical Sciences
University of Brasilia
Brasilia, Brazil

**REFERENCES**

1. Vermeeren A, Coenen AM. Effects of the use of hypnotics on cognition. *Prog Brain Res*. 2011;190:89–103.
2. Gunja N. In the Zzz zone: the effects of Z-drugs on human performance and driving. *J Med Toxicol*. 2013;9:163–171.
3. James SP, Mendelson WB. The use of trazodone as a hypnotic: a critical review. *J Clin Psychiatry*. 2004;65:752–755.
4. Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. *J Clin Psychiatry*. 2005;66:469–476.
5. Bossini L, Casolari I, Koukoua D, et al. Off-label uses of trazodone: a review. *Expert Opin Pharmacother*. 2012;13:1707–1717.
6. Stahl SM. *Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications*. 3rd ed. Cambridge: NY: Cambridge University Press; 2008.
7. Roth AJ, McCall WV, Liguori A. Cognitive, psychomotor and polysomnographic effects of trazodone in primary insomniacs. *J Sleep Res*. 2011;20:552–558.
8. Rush CR, Madakasira S, Hayes CA, et al. Trazodone and triazolam: acute subject-rated and performance-impairing effects in healthy volunteers. *Psychopharmacology*. 1997;131:9–18.
9. Camargos EF, Louzada LL, Quintas JL, et al. Trazodone improves sleep parameters in Alzheimer disease patients: a randomized, double-blind, and placebo-controlled study. *Am J Geriatr Psychiatry*. 2014;22:1565–1574.
10. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res*. 1975;12:189–198.
11. Wechsler D. *WAIS-III Wechsler Memory Scale*. 3rd ed. San Antonio, TX: Psychological Corporation; 1997, manual.
12. Wechsler D. *WAIS-III Wechsler Adult Intelligence Scale*. 3rd ed. San Antonio, TX: Psychological Corporation; 1997, manual.
13. Greenblatt DJ, Friedman H, Burstein ES, et al. Trazodone kinetics: effect of age, gender, and obesity. *Clin Pharmacol Ther*. 1987;42:193–200.
14. Burns M, Moskowitz H, Jaffe J. A comparison of the effects of trazodone and amitriptyline on skills performance by geriatric subjects. *J Clin Psychiatry*. 1986;47:252–254.
15. Sasada K, Iwamoto K, Kawano N, et al. Effects of repeated dosing with mirtazapine, trazodone, or placebo on driving performance and cognitive function in healthy volunteers. *Hum Psychopharmacol*. 2013;28:281–286.
16. Obermann KR, Morris JC, Roe CM. Exploration of 100 commonly used drugs and supplements on cognition in older adults. *Alzheimers Dement*. 2013;9:724–732.
17. Riedel WJ, Mehta MA, Unema PJ. Human cognition assessment in drug research. *Curr Pharm Des*. 2006;12:2525–2539.

**AUTHOR DISCLOSURE INFORMATION**

The authors declare no conflicts of interest.
period is 298 (age, 16–89 y; mean and median, 46 y; 153 females and 145 males). Catatonia has been diagnosed at some time during the course of 8 (2.7%) of these: 4 men and 4 women aged 24 to 67 years at the time of diagnosis. In 2 instances, the diagnosis was made or suspected during the intake evaluation. In no patient had it been made earlier by another provider. In retrospect, it might have been made at intake in 2 of the patients but was not. In Table 1, the characteristic features of catatonia are presented in 5 categories. The features were required to have had an onset, at that time to be new or considerably accentuated, to be considered catatonic. The diagnosis was difficult in only one instance, once it was considered, and here, a clear response to benzodiazepine was confirmatory.

Note the frequency with which catatonia is chronic (if the disorder is untreated or if benzodiazepine is not given coincidentally for another reason). In no patient for whom benzodiazepine was administered for catatonia was there a failure to respond, even if the features previously had waxed and waned chronically (benzodiazepine has been continued indefinitely in these patients, and a relapse that could not be relieved through dose adjustment did not occur in any of them); sometimes, considerable dose adjustment has been required (Case Report, Supplemental Digital Content 1 [http://links.lww.com/JCP/A251], and in 2 cases, the dose needed proved to be relatively high (lorazepam, total of 10 mg daily in 1 instance; diazepam, total of 30 mg daily in another). In the 2 patients with autism spectrum disorder (ASD) whose catatonia was of an acute pattern for whom benzodiazepine was tried and effective, the drug could be successfully tapered off some months later in 1 patient (severe environmental stress had been the triggering event for catatonia) and the other patient was lost to follow-up.

Five of the 8 patients with catatonia are high school graduates (3 patients have an ASD). In 2 patients, the terminal degree is a bachelor’s degree (both patients have an ASD), and in 1 patient, it is a doctorate degree (the patient has an ASD); 1 is a graduate of a 2-year course in a community college. Four patients are employed; the fifth patient is a competent homemaker. The other 3 patients have mild or pronounced intellectual impairment (all patients have an ASD); none of the patients is employed gainfully enough for independent living.

The most surprising finding within this report is the prevalence of ASD, or likely ASD, as the underlying or predisposing condition for catatonia: 6 of the 8 (Table 1). In none of the patients with ASD did catatonia emerge as a complication of depression. Autism spectrum disorder has been diagnosed or considered likely in 26 (9%) of the 298 patients in the practice, a diagnosis suspected before the patient entered the practice in only 3 patients. Catatonia has therefore complicated the course of 23% of these patients with ASD. A case report for 1 of the 8 patients, who has experienced both ASD and catatonia, is included in the Supplemental Digital Content 1 (http://links.lww.com/JCP/A251); it illustrates several of the observations previously described.

### DISCUSSION

Several current authorities on catatonia suggest that a disorder of mood, especially mania, is the most prevalent comorbid condition. Yet, ASD, which is not a disorder of mood, is the most common preconception for catatonia in adults if the practice described here typifies the nonhospitalized world. Of course, it may not so typify that, but at the least, we may say that it is not true everywhere that most catatonic adults have a mood disorder: ASD is very possibly much more common in such patients than the study of hospital units has revealed.

#### TABLE 1. Clinical Features

| Case | Mutism* | NEG† | VI‡ | PERSEV§ | EXCIT¶ | BZD‖ | BFCRS§ | Pattern** | DSM-5†† |
|------|---------|------|-----|---------|-------|-----|-------|-----------|--------|
| 1    | +       | −    | +   | −       | −     | +   | 3     | Chronic   | ASD    |
| 2    | +       | +    | +   | +       | +     | n/a | 17    | Chronic   | ASD    |
| 3    | +       | +    | −   | +       | +     | +   | 8     | Acute and recurrent | ASD    |
| 4    | +       | +    | +   | +       | +     | +   | 24    | Acute     | ASD    |
| 5    | +       | +    | +   | +       | +     | −   | 15    | Acute     | ASD    |
| 6    | +       | +    | +   | +       | +     | +   | 23    | Chronic   | ASD    |
| 7    | +       | +    | +   | +       | −     | n/a | 22    | Acute     | Bipolar I |
| 8    | +       | −    | +   | +       | −     | +   | 8     | Acute     | Schizophrenia |

*Relative to the patient’s fluent, usual speech, including uncharacteristic pausing when it derails effective communication.
†Negativism. Here defined as an apparently motiveless resistance to interference or suggestion, which may be passive or active (doing the opposite) and may be accompanied by either hostility or indifference; included are refusal to eat or drink, refusal to obey conventional propriety for urination or defecation, and gegenhalten.
‡Volitional instability. Any (1 or more) of the following: purposeless posturing, schnauzkämpf, immobility, ambitendency, Sperrung, automatic obedience, and stupor.
§Perseverations. Any (1 or more) of the following: echolalia, echopraxia, stereotypes, grimacing, verbièrgerung, palilalia, staring, and mannerism.
¶Excitement. Any (1 or more) of the following: spells of ceaseless, largely purposeless activity; parakinesia; combativeness; nudism; impulsivity; as well as repetitive and indelicate self-injury (non suicidal).
‖Responsive to benzodiazepine: lorazepam in 3 patients, clonazepam in 2 patients, and diazepam in 1 patient.
§Bush-Francis Catatonia Rating Scale and see Supplemental Digital Content 1, at http://links.lww.com/JCP/A251.
**The course of catatonia. Chronic means at least some features presented, as judged through clinical history taking, in childhood or in adolescence and waxing and waning since.
††The principal psychiatric disorder present, other than catatonia. In addition, other psychiatric comorbidities were present in some patients.
‡‡The 1 patient who did not meet the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria for catatonia but did qualify for the diagnosis on the basis of the Bush-Francis Catatonia Screening Instrument (2 or more of the first 14 items on the Bush-Francis Catatonia Rating Scale are scored at 1 or higher).

BFCRS indicates Bush-Francis Catatonia Rating Scale; DSM-5, Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition; n/a, not tested or not documented.
That catatonia commonly supervenes in ASD is not a new observation and is one that has recently been reviewed in depth. However, how do we account for, if the results of this study are confirmed in studies to come, catatonia in outpatients most often complicating ASD and in inpatients most often complicating a mood disorder? Possibly, catatonia complicates a condition of disordered mood rarely (only once in 6 years in this practice), but when it does, it is abrupt, new and dramatic, and thereby influential in the decision to recommend hospitalization, whereas catatonia in ASD is more often a chronic waxing and waning occurrence, as in the case reported here (Table 1). Hence, hospitalization perhaps is prompted much less often.

This last comment points to a diagnostic matter of importance. Some have argued that the features of catatonia overlap with those of autism itself; therefore, in persons with autism, to be considered catatonic, they must constitute a distinct change, as was the policy for the diagnosis in this report. Clinicians, once they consider the diagnosis of catatonia, must be performing well because patients with autism whom they choose to treat for comorbid catatonia are uniformly responding (Table 1; Case Report, Supplemental Digital Content 1 http://links.lww.com/JCP/A251).

Very possibly, if this article and its case report are representative, in this region, a widespread attention deficit in medical and psychiatric diagnostic practice exists for diagnosing ASD in adults, perhaps because the literature on doing so is still small.12,13

To what extent such diagnostic oversight takes place generally in the United States and elsewhere is yet unknown. However, another, perhaps even more critical, concern about underdiagnosis is that of catatonia. Two excellent books have been published in the past decade or so, in part motivated by the recognition that catatonia is underappreciated.3,4 Yet, diagnostic failures and delays continue, including my own (Case Report, Supplemental Digital Content 1 http://links.lww.com/JCP/A251), and this is true, although the diagnosis of catatonia is easy, once considered, and once the diagnosis is made, treatment (benzodiazepine, electroconvulsive therapy, or both) is almost always effective (Table 1). An emphatic suggestion is this: put the Bush-Francis Catatonia Rating Scale to clinical use; it is practical, self-explanatory, and confident enhancing.5,6,16 Because its use in the setting of autism has not been specifically validated, alternatives have been suggested.7 The experience reported herein, however, suggests that, with the caveat that the catatonic features must at their onset be either new or newly and distinctly exacerbated (see previous), it works well.

**AUTHOR DISCLOSURE INFORMATION**

The author declares no conflicts of interest.

Dr Johnson is currently in private practice of general psychiatry in Walla Walla, WA. He was formerly affiliated with the Department of Psychiatry and Human Behavior at Thomas Jefferson University Hospital in Philadelphia, PA.

Supplemental digital contents are available for this article. Direct URL citation appears in the printed text and is provided in the HTML and PDF versions of this article on the journal’s Web site (www.psychopharmacology.com).

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Robert Arnold Johnson, MD
robertarnoldjohnson@gmail.com

**REFERENCES**

1. Johnson J. Catatonia: the tension insanity. Br J Psychiatry. 1993;162:733–738.
2. Taylor MA, Fink MD. Catatonia in psychiatric classification: a home of its own. Am J Psychiatry. 2003;160:1233–1241.
3. Fink M, Taylor MA. Catatonia: A Clinician’s Guide to Diagnosis and Treatment. Cambridge, England: Cambridge University Press; 2003.
4. Caroff SN, Mann SC, Francis A, et al. Catatonia: From Psychopathology to Neurobiology. Washington, DC: American Psychiatric Publishing; 2004.
5. Bush G, Fink M, Petrides G, et al. Catatonia. I. Rating scale and standardized examination. Acta Psychiatr Scand. 1989;93:129–136.
6. Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition. Arlington, VA: American Psychiatric Association; 2013.
7. Mazzone L, Postorino V, Valeri G, et al. Catatonia in patients with autism: prevalence and management. CNS Drugs. 2014;28:205–215.
8. Wing L, Shah A. Catatonia in autistic spectrum disorders. Br J Psychiatry. 2000;176:357–362.
9. Wing L, Shah A. A systematic examination of catatonia-like clinical pictures in autism spectrum disorders. Int Rev Neurobiol. 2006;72:21–39.
10. Wachtel LE, Kahng S, Dhossche DM, et al. ECT for catatonia in an autistic girl. Am J Psychiatry. 2008;165:329–333.
11. Haq AU, Ghaziuddin N. Maintenance electroconvulsive therapy for aggression and self-injurious behavior in two adolescents with autism and catatonia. J Neuropsychiatr Clin Neurosci. 2014;26:64–72.
12. Brugha TS, McManus S, Bankart J, et al. Epidemiology of autism spectrum disorders in adults in the community in England. Arch Gen Psychiatry. 2011;68:459–465.
13. Robinson L, Spencer MD, Thomson LD, et al. Evaluation of a screening instrument for autism spectrum disorders in prisoners. PLoS One. 2012;7:e1–836078.
14. Ghaziuddin N, Dhossche D, Marcotte K. Retrospective chart review of catatonia in child and adolescent psychiatric patients. Acta Psychiatr Scand. 2012;125:33–38.
15. Tuerlings JH, van Waarde JA, Verwey B. A retrospective study of 34 catatonic patients: analysis of clinical care and treatment. Gen Hosp Psychiatry. 2010;32:631–635.
16. Sienaert P, Rooseleer J, De Fruyt J. Measuring catatonia: a systematic review of rating scales. J Affect Disord. 2011;135:1–9.

As-Needed Use of CYP2D6 Inhibitors

Sexual adverse effects of antidepressant medications (22%–43%) are highest among selective serotonin reuptake inhibitors (SSRIs) as the mainstream treatment for a wide range of anxiety and mood disorders. Despite the favorable side effect profile of SSRIs, their low price, and well-studied effectiveness, sexual adverse effects may prevent many patients from their use or titration to the optimal dose. Different strategies have been used for treatment of sexual adverse effects of SSRIs including switching to or addition of another antidepressant with less sexual adverse effects (bupropion, trazodone, mirtazapine),2 addition of non–antidepressant agents (sildenafil, yohimbine),3 or addition of antihistaminic agents (loratadine and cyproheptadine).4

Cyproheptadine is an H1 receptor–blocker antihistamine with 5-hydroxytryptamine 2 serotonin–blocking properties, which has been reported to be effective in the treatment of SSRI-related anorgasmia and delayed ejaculation in males.5,6 These reports have used cyproheptadine at 2 to 16 mg daily or as-needed doses 1 to 2 hours before sex. One concern about regular daily dose is reversal of the antidepressant effects of